Compare Natera Inc. Common Stock (NTRA) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Stryker Corporation — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Stryker Corporation trades at $285.51 (market cap $108.02B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays a 1.25% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| NTRA | SYK | |
|---|---|---|
Market Cap | $57.03B | $108.02B |
Volume | 1,131,157 | 2,222,698 |
Sector | Health | Health |
52-Week High | $425.64 | $388.35 |
52-Week Low | $179.42 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $56.18B | $119.49B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Stryker (SYK) trades at $282.63, showing minimal daily change. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company maintains strong profitability with a 14.43% net income margin and 16.51% ROE. Recent Q2 2026 earnings beat expectations, though Q1 2026 was a miss. Analyst sentiment is strongly bullish with a $365.89 consensus price target, but recent news highlights legal investigations and a manufacturing issue disclosure that caused an 8.8% share drop in early September 2026.
The outlook for SYK is cautiously optimistic. Strong fundamentals and analyst support suggest upside potential, but near-term risks from legal scrutiny and operational challenges could pressure the stock. Investors should weigh robust financial health against headline volatility ahead of Q3 2026 earnings on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
